Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
10
×
san diego blog main
san diego top stories
10
×
new york blog main
biotech
boston blog main
boston top stories
clinical trials
national top stories
new york top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
drugs
bristol-myers squibb
intercept pharmaceuticals
nonalcoholic steatohepatitis
san diego
startups
akcea therapeutics
avexis
cancer
cancer immunotherapy
celgene
What
disease
10
×
drug
approved
fda
liver
medicines
nash
roundup
akcea
bio
companies
control
fatty
fight
known
medicine
new
news
patients
race
year
according
add
advanced
ago
alnylam
alnylam’s
alzheimer's
american
amyloidosis
approval
ash
attr
available
bacteria
bad
battle
better
bff
big
Language
unset
Current search:
" national blog main "
×
disease
×
" san diego top stories "
×
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
California Life Sciences Fueled by Education, Established Companies
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections